Month: February 2022

Fact.MR – A Market Research and Competitive Intelligence Provider: As per the latest research conducted by the Fact.MR, the global viral disease diagnosis market is projected to exhibit healthy growth, surging at a CAGR of 8% during the forecast period between 2021 and 2031.

Successive outbreaks of various contagious viruses such as Ebola, Influenza A & Influenza B, Hantavirus, Chikungunya, and SARS-CoV virus among others globally have fuelled the demand for viral disease diagnosis.

According to a study by the World Health Organization (WHO), approximately 229,858,719 people across the world were diagnosed with COVID-19, which caused around 4,713,543 deaths as of September 2021. Timely diagnosis has therefore become indispensable to counter to spread of COVID-19. This has in turn fuelled the demand for viral disease diagnosis around the world.

Request a report sample to gain comprehensive insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=6920

Regulatory bodies are increasingly examining the effectiveness of novel diagnostic products and authorizing the product use to contain viral diseases. For instance, the U.S. Food and Drug Administration (FDA) provided Emergency Use Authorization (EUA) for rapid diagnosis of COVID-19, Sofia 2 SARS Antigen FIA to Quidel Corporation, a diagnostic healthcare company, in May 2020. These advancements are expected to drive the growth of the market through the forecast period.

North America is projected to emerge as the most remunerative region in the global landscape. Growth in the region will be driven by the large presence of leading market players and the high prevalence of viral diseases in the countries such as the U.S. and Canada.

“Leading players are emphasizing on launching disease-specific diagnostic kits such as influenza A/B combo testing kit using new techniques like microarray to provide improved accuracy for large-scale sample diagnosis,” says a Fact.MR analyst.

Key Takeaways from the Viral Disease Diagnosis Market Survey

• The U.S. is anticipated to account for the dominant share in the North America market, driven by the presence of favorable reimbursement policies.
• The market for viral disease diagnosis in the U.K. is expected to register steady growth, favored by high awareness regarding early diagnosis of chronic ailments and availability of favorable medical reimbursement policies.
• China is projected to lead the Asia Pacific market due to the high prevalence of viral diseases such as Chikungunya, Influenza, and coronavirus in the country.
• Favored by increasing investment in the development of advanced medical healthcare infrastructure, India is expected to emerge as a highly attractive market in Asia Pacific through 2031.
• In terms of end use, hospitals are predicted to account for a significant share in the market, driven by the availability of advanced medical infrastructure and a high number of patients’ visits.

Key Drivers

• Rising prevalence of viral diseases such as Influenza A & B, Ebola, Chikungunya, and others across North America, Latin America, and Asia Pacific is fuelling the demand for viral disease diagnosis.
• Increasing healthcare expenditure and investment towards improving access to advanced healthcare facilities, especially in emerging economies will present a conducive environment for the growth of the market.

Key Restraints

• High cost of viral disease diagnosis such as molecular techniques and viral isolation is affecting the sales across cost-sensitive countries such as India and Brazil.

To gain in-depth insights on Viral Disease Diagnosis Market, request methodology at

https://www.factmr.com/connectus/sample?flag=RM&rep_id=6920

Competitive Landscape

Leading players operating in the viral disease diagnosis market are focusing of launching new products and receiving product approvals to expand their market share. Besides this, some of the companies are engaging in collaborations, agreement, merger, and acquisition with other players to increasing their revenue share. For instance,

• In May 2020, ACON Laboratories, a medical diagnostic Manufacturer based in the U.S., announced introducing its new product, Point-of-care SARS-COV-2 IgG/IgM Rapid Test for the identification of IgG and IgM antibodies related to COVID-19.

• In March 2020, Abbott, a multinational medical devices and health care company headquartered in the U.S., announced launching a new diagnostic product, the ID NOW COVID-19 test for rapid assessment of the virus in the U.S.

Some of the leading players in the market profiled by Fact.MR are:

• Thermo Fisher Scientific
• Adaltis S.r.l
• R-Biopharm AG
• Siemens Healthcare Private Limited
• Toronto Bioscience
• Merck KGaA
• Abbott Laboratories
• BioMérieux SA
• Cepheid
• Epitope Diagnostics Inc.
• F. Hoffmann-La Roche Ltd
• Elabscience Biotechnology Inc.
• Mylab Discovery Solutions Pvt. Ltd.
• Altona Diagnostics GmbH
• TIB Molbiol
• Luminex Corporation
• Becton
• Dickinson and Company.

More Valuable Insights on Viral Disease Diagnosis Market

Fact.MR, in its new report, offers an unbiased analysis of the global viral disease diagnosis market, analyzing forecast statistics through 2021 and beyond. The survey reveals growth projections on in viral disease diagnosis market with detailed segmentation:

• By Product Type
  • Direct specimen examination
  • Viral isolation
  • Molecular techniques
  • Microarray technique
  • Serodiagnostic kits
• By End-Use
  • Homecare
  • Diagnostic Centers
  • Nursing homes
  • Hospitals
  • Clinics
  • Laboratories
• By Virus
  • HIV infection
  • SARS-CoV
  • Influenza viruses
  • hepatitis C virus
  • hepatitis B virus
  • hepatitis A virus
  • Influenza A and Influenza B viruses
• By Region
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East and Africa

Key Questions Covered in the Viral Disease Diagnosis Market Report 

• The market survey also highlights projected sales growth of the viral disease diagnosis market between 2021 and 2031
• The report offers insight into viral disease diagnosis demand outlook for 2021-2031
• Viral disease diagnosis market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, collaborations or partnerships, and others
• Viral disease diagnosis market analysis identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry

Rapid Medical Diagnostic Kits Market– Infectious disease incidence has been steadily increasing over the last few decades, driving up demand for rapid medical diagnostic kits around the world. The need to detect novel pathogens that cause diseases is propelling the market forward. The low cost of rapid medical diagnostic kits is propelling market growth. Blood glucose testing is in high demand, and it has been growing at the quickest rate of all types of tests across all geographies. Technology advancements and strategic alliances by key market players have paved the way for rapid medical diagnostic kit innovations.

Viral Antigens Market– The use of viral antigens in vaccine development by clinicians and researchers has been rapidly growing. The vaccine development research is being driven by advancements in image analysis software and informatics platforms for viral antigen identification, which is projected to fuel the viral antigens market expansion. ELISAs are frequently used as a reliable method for detecting and diagnosing viral infection. The adoption of ELISA for detecting viral antigens is projected to contribute significantly to the bottom lines of stakeholders.

Influenza A/B Combo Testing Market- The tremendous burden of a viral pandemic is driving the expansion of the global Influenza A/B combo testing market, resulting in a surge in demand for Influenza A/B combo testing. Influenza A/B combo testing accuracy, sensitivity, and advance diagnosis are always being improved by research and healthcare infrastructure. The market is being fueled further by increased awareness of the pandemic and early detection, as well as the government’s proactive aids and programming. The leading players are concentrating their efforts on developing novel Influenza A/B combo testing kits that are quick to diagnose large-scale samples.

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

 

Fact.MR’s latest study examines key trends prevalent across the particle-enhanced turbidimetric immunoassays market. It uncovers the factors driving the market in terms of application and end user. The report is intended at presenting an overview of drivers, restrains, and opportunities for prominent market players along with key stakeholders

Fact.MR – A Market Research and Competitive Intelligence Provider: As per Fact.MR, the global particle-enhanced turbidimetric immunoassays market is projected to exhibit strong growth during the forecast period, from 2021 and 2031.

Particle-enhanced turbidimetric immunoassays (PETIA) has a diverse applications in medical intuitions and pharmaceutical & biotechnology companies. Its ability to integrate with any kind of chemical analyzers, assisting in the development of novel drugs and bionics, will boost the market.

In addition to this, increasing adoption of PETIAs kits and regents for bulk antibody testing of novel diseases such as Ebola and COVID-19 is exponentially driving the market.

Rising prevalence of infectious diseases such as influenza, tuberculosis, and chickenpox among others will emerge as a chief growth driver. According to the World Health Organization (WHO), around 10 million cases of tuberculosis were reported across the world, causing nearly 1.5 million fatalities in 2020.

This has resulted in higher demand for quick and effective diagnosis of the aforementioned diseases, which is expected to create growth opportunities for the market.

Request a report sample to gain comprehensive insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=6899

As per Fact.MR, North America is projected to account for the lion’s share in the global market. Growth in the region is driven by high prevalence of infectious diseases.

Also, increasing PETIA application across endocrinology, cardiology, and oncology for quantitative measurement of proteins, pathogens, and other molecules in body fluids, such as plasma will aid the growth in the market.

“In vitro diagnostics (IVD) companies are increasingly adopting PETIA technology for COVID-19 antibody diagnosis. Demand for higher throughput and cost-effective open platform testing, with shorter time-to-result compared to other immunoassay systems will aid the expansion of the market,” says a Fact.MR analyst.

Key Takeaways from the Particle-Enhanced Turbidimetric Immunoassays Market Study

• The U.S. is anticipated to dominate the market in North America, owing to high presence of diagnostics centers and availability of favorable medical reimbursement policies.
• The U.K. and Germany are projected to cumulatively account for the largest share in the Europe market, favored by increasing number of medical research and development activities for novel drug development.
• China is forecast to account for a substantial revenue share in the Asia Pacific market, due to high prevalence of infectious diseases such as tuberculosis in the country.
• India is expected to emerge as a highly remunerative market, on the back of increasing demand for cost-effective and bulk testing diagnostics devices.
• Based on end user, hospitals are estimated to remain the most lucrative segment, driven by the presence of advanced diagnostics infrastructure and high patient preference.

Key Drivers

• Surging demand for quick results providing diagnostic devices for quantitative testing of COVID-19 across the countries such as China, India, the U.S., and others are driving the sales of particle-enhanced turbidimetric immunoassays.
• Increasing research and development activities across pharmaceutical and biotechnological companies for the development of novel drugs and bionics for various disease therapeutics is propelling the demand.

Key Restraints

• Stringent regulations implemented on the approval and commercialization of immunoassay devices and consumables across North America and Europe are restraining the growth of the market.
• Technological hurdles caused by the immunoassay kits and reagents such as false negatives, low detection limits of the antibodies, and cross-reactivity of the antibodies are expected to hinder the sales.

To learn more about Particle-Enhanced Turbidimetric Immunoassays Market, you can get in touch with our Analyst at:

https://www.factmr.com/connectus/sample?flag=AE&rep_id=6899

Competitive Landscape

Leading players in the global particle-enhanced turbidimetric immunoassays market are emphasizing on developing new products using PETIA technique. They are adopting strategies such as novel product launch, collaboration, mergers and acquisitions expand their product portfolio and global presence. For instance,

• In 2020, Gentian Diagnostics ASA, a global medical diagnostics company, announced launching COVID-19 antibody test using its innovative PETIA technology. The Genetian antibody test is a turbidimetric COVID-19 assay for bulk testing of the coronavirus. The product launch will assist the company to expand its product portfolio and increase in market share.

• In August 2020, TRIMERO Dianostics, a medical technology manufacturer based in Spain, announced adding a new CE-IVD marked Serum Amyloid A, particle-enhanced turbidimetric immunoassay to enhances its product catalogue.

Some of the leading players in the market profiled by Fact.MR are:

• Gentian Diagnostics ASA
• Eurospital
• Calpro
• Thermo-Fisher Scientific
• Buehlmann
• Biotec
• Abbott Laboratories
• F.Hoffmann-La Roche
• Siemens AG
• Danaher Corporation
• Diasorin SPA
• Sysmex Corporation
• Biomerieux SA
• QIAGEN
• Agilent Technologies, Inc

More Valuable Insights on Particle-Enhanced Turbidimetric Immunoassays Market

Fact.MR, in its new report, offers an unbiased analysis of the global particle-enhanced turbidimetric immunoassays market, analyzing forecast statistics through 2021 and beyond. The survey reveals growth projections on in particle-enhanced turbidimetric immunoassay market with detailed segmentation:

·By Application:

• Infectious Diseases
• Endocrinology
• Cardiology
• Oncology
• Bone and Mineral Diseases
• Autoimmune Disorders
• Others

·By End User:

• Hospitals
• Academic and Research Institutions
• Pharmaceutical and Biotechnology Companies
• Others

·By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

 Key Questions Covered in the Particle-Enhanced Turbidimetric Immunoassays Market Report 

• The market survey also highlights projected sales growth of the particle-enhanced turbidimetric immunoassays market between 2021 and 2031
• The report offers insight into particle-enhanced turbidimetric immunoassays demand outlook for 2021-2031
• Particle-enhanced turbidimetric immunoassay market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, collaborations or partnerships, and others
• Particle-enhanced turbidimetric immunoassays market analysis identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry

Explore Fact.MR’s Coverage on the Healthcare Domain –

Immunoassay Market– The database of biomarkers utilized by industry participants to design new assays that detect the onset of a disease or ailment has grown as a result of rapid advances in genomes and proteomics. The global immunoassays market is expected to grow at a rapid pace. With the growing database on genetics and biomarkers of numerous infectious pathogens, key firms are investing in the development of innovative immunoassays in the infectious diseases area. For the diagnosis of infectious disorders, immunoassay analyzers such as enzyme-linked immunosorbent assay (ELISA) and others are preferred.

Influenza Diagnostics Market– Influenza, also known as ‘the flu,’ is a contagious illness caused by the influenza virus. To identify and diagnose influenza, a variety of conventional and molecular diagnostic tools are used. Advanced technologies now allow for highly effective and precise influenza diagnosis. Factors such as rising influenza prevalence, increased awareness of the importance of early detection with specific diagnostic tests, the development of CLIA-waived point-of-care molecular influenza tests, and a shift in focus from centralized laboratories to decentralized point-of-care testing are expected to drive the global market forward in the coming years.

Chemiluminescence Immunoassay (CLIA) Analyzers Market– The number of tests that use Chemiluminescence Immunoassay Analyzers (CLIA) techniques is expected to grow as a result of technical advancements in illness detection, as well as increased demand for preventive diagnosis and treatment monitoring. The worldwide chemiluminescence immunoassays market is expected to benefit from the COVID-19 pandemic. Several industry players and healthcare organizations are investing in the development of CLIA-based diagnostic tests to determine growth inhibition methods to the novel coronavirus utilizing a variety of ways.

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com